COMMUNIQUÉS West-GlobeNewswire

PracticeLink Reveals Evolved Brand Identity Focused on Clarity, Simplicity and Trust for Healthcare Providers and Recruiters
02/04/2026
Updated identity reflects a clearer standard for what clinicians and hiring teams can expect—delivered steadily instead of disruptively ST. LOUIS and HINTON, West Virginia, April 02, 2026 (GLOBE NEWSWIRE) -- [...]
Catalyst MedTech Announces Acquisition of X3D
02/04/2026
Expands OEM Platform and Strengthens Leadership in Nuclear Medicine Imaging PITTSBURGH, April 02, 2026 (GLOBE NEWSWIRE) -- Catalyst MedTech, a national leader in nuclear medicine and molecular imaging solutions, today [...]
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
02/04/2026
TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has entered into a securities [...]
Dr. Joseph Mikhael Steps into New Role as Medical Advisor for the International Myeloma Foundation
02/04/2026
STUDIO CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced that Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO has taken the step of transitioning his role as Chief [...]
Protecting Healthy Futures: Unity Consortium Urges Families to Prioritize Adolescent Health During Immunization Action Week
02/04/2026
AIAW26 Runs April 6-10, Highlights the Critical Role of Well-Visits and AAP-Recommended Immunizations VENTNOR CITY, N.J., April 02, 2026 (GLOBE NEWSWIRE) -- Unity® Consortium, a non-profit dedicated to adolescent and [...]
Sienna Announces First Quarter 2026 Results Release Date and Conference Call
02/04/2026
MARKHAM, Ontario, April 02, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) announced that it will report its 2026 first quarter results after market close on Tuesday, May 5 [...]
Prenetics Announces NBA Champion and Two-Time MVP Giannis Antetokounmpo as IM8 Global Partner and Shareholder in Multi-Year Partnership
02/04/2026
Giannis becomes the first NBA athlete shareholder in a NASDAQ-listed health and longevity brand, joining the fastest supplement company ever to reach $100M ARR in just 11 months Giannis unlocks 35 million followers [...]
From Lab Fiber to Luxury Fabric: Kraig Biocraft Laboratories Targets Apparel First with Engineered Spider Silk
02/04/2026
DENVER, April 02, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com ) -- Kraig Biocraft Laboratories (OTCQB: KBLB) is advancing a transgenic silkworm platform designed to produce recombinant spider silk at commercial [...]
MIMEDX to Sponsor Leading Advanced Wound Care Conferences
02/04/2026
Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group [...]
MyGevity Announces Nationwide Launch of Integrated Health Data Platform
02/04/2026
New system centralizes at-home DNA testing, biological age assessment, and lab diagnostics into a unified reporting experience ST. PETERSBURG, FL, April 02, 2026 (GLOBE NEWSWIRE) -- MyGevity announced the nationwide [...]
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
02/04/2026
Dose-Dependent Efficacy Results : As of the latest data cut, muzastotug achieved a 31% (8/26) confirmed overall response rate (ORR) in the combined 20 mg/kg dose cohorts, showing a clear improvement over the 13% ORR (5/ [...]
Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein
02/04/2026
NTR-1011 demonstrated a favorable safety, tolerability, and immunogenicity profile across multiple dose levels of intravenous (IV) and subcutaneous (SC) administrations NTR-1011 displayed a predictable pharmacokinetic ( [...]
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
02/04/2026
Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026 Timeline for submission of NDA dossier of deucrictibant IR for on- [...]
Burning Rock Announces Founder’s Purchase of Its ADSs
02/04/2026
GUANGZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in [...]
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02/04/2026
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies [...]
Arch Biopartners Closes Non-Brokered Private Placement
02/04/2026
TORONTO, April 02, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today it has closed a non-brokered private placement offering of 1,000,000 [...]
Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02/04/2026
Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findings Patients in the TED studies demonstrated greater levels of [...]
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
02/04/2026
Lichen planopilaris (LPP) is a highly morbid inflammatory scalp disorder that causes generally irreversible scarring hair loss, often accompanied by profound pain, itch, and burning sensations; no FDA-approved therapies [...]
Pharming Group announces the filing of its 2025 Annual Report and Form 20-F
02/04/2026
Leiden, the Netherlands, April 2, 2026: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced the filing of its Annual Report for the year ended December 31, 2025. [...]

Pages